Christina Alvarez
Elmhurst, NYNPI 1821695438
Payments from drug & device makers
Across 250 payments — averaging $25.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novo Nordisk$781
- AbbVie$775
- AstraZeneca$697
- Lilly USA, LLC$692
- Merck$384
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,27698%
- Education$1092%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 30 | $1,057 |
| Novo Nordisk | 39 | $781 |
| AbbVie | 26 | $775 |
| AstraZeneca | 18 | $697 |
| Lilly USA, LLC | 32 | $692 |
| Merck | 18 | $384 |
| Pfizer | 13 | $355 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $301 |
| Astellas Pharma US Inc | 5 | $188 |
| Ardelyx, Inc. | 6 | $172 |
| Phathom Pharmaceuticals, Inc. | 4 | $91 |
| Amarin Pharma, Inc. | 4 | $83 |
| Kowa Pharmaceuticals America, Inc. | 4 | $79 |
| Teva Pharmaceuticals USA, Inc. | 4 | $72 |
| Novartis | 4 | $71 |
| Boehringer Ingelheim | 3 | $70 |
| Seqirus USA Inc | 3 | $69 |
| E.r. Squibb & Sons, L.L.C. | 2 | $52 |
| Redhill Biopharma Inc. | 2 | $50 |
| Renalytix AI, Inc. | 2 | $47 |
| Phadia US Inc. | 2 | $39 |
| GSK | 2 | $38 |
| Sanofi-aventis U.S. LLC | 1 | $36 |
| Johnson & Johnson | 1 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Saluda Medical Americas, Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $20 |
| Alk-abello, Inc | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 31 | $30,301 |
| ProliaDenosumab | 11 | $17,578 |
| VascepaIcosapent Ethyl | 23 | $11,038 |
| Repatha SureclickEvolocumab | 16 | $8,443 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,385 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $4,953 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $2,173 |
| Diclofenac Sodium | 24 | $1,759 |
| Atorvastatin Calcium | 71 | $987 |
| Metoprolol Succinate | 22 | $647 |
| Levothyroxine Sodium | 31 | $566 |
| Losartan Potassium | 41 | $534 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $505 |
| Omeprazole | 33 | $446 |
| Fluticasone Propionate | 43 | $409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $692 | $30,30131 claims |
| AmgenProlia | $1,057 | $17,57811 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $38 | $12,33925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.